LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced continued advancement of its mobile healthcare application ecosystem, including applications being prepared for anticipated future availability through both the Apple App Store and Google Play Store. The company also revealed that early-stage platform subscribers have surpassed 1,000, a milestone management believes reflects growing interest in its healthcare technology ecosystem.
The applications under development are intended to support various telehealth, healthcare communication, patient engagement, provider coordination, emergency response, and AI-assisted healthcare support initiatives as part of the company’s broader digital healthcare infrastructure strategy. Management stated that development, testing, integration, and platform optimization efforts are ongoing for multiple mobile healthcare applications aimed at improving healthcare accessibility in emerging markets, particularly Latin America.
Some applications are being prepared for submission to the Apple App Store and Google Play Store following continued development, internal testing, platform review processes, and regulatory considerations. The company emphasized that the applications and related platform technologies remain under active development and have not yet been fully commercialized or broadly deployed. No assurance can be provided regarding the timing of any public release, regulatory progression, or operational success.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated: “We are continuing to advance development of our mobile healthcare application ecosystem with the goal of expanding accessibility and healthcare connectivity through both Apple and Android mobile platforms. Surpassing 1,000 early-stage users represents an encouraging milestone as we continue refining and expanding our broader digital healthcare infrastructure initiatives.”
The company believes continued user engagement may provide valuable operational feedback as development progresses and additional platform functionality is evaluated. LataMed AI’s broader technology initiatives remain focused on scalable healthcare infrastructure solutions for underserved and developing markets where access to healthcare coordination, telehealth services, and digital tools is limited or fragmented.
For more information, visit LataMed AI's website or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
This announcement is significant for the digital health industry, as it signals progress in bringing AI-powered telehealth solutions to emerging markets where healthcare infrastructure is often lacking. Surpassing 1,000 early subscribers indicates initial market validation, which may attract further investment and partnerships. For business leaders, this development highlights the growing potential of mobile health applications in underserved regions, offering opportunities for cost-effective healthcare delivery and data-driven analytics. However, risks remain, including regulatory hurdles, commercialization delays, and the company’s development-stage status, as noted in the forward-looking statements.
